1 minute reading time (204 words)

Novel and Emerging Treatment Strategies for Advanced Classical Hodgkin Lymphoma With Kami Maddocks, MD, and Kelly Brassil, PhD, RN, FAAN

Hodgkin lymphoma is a rare malignancy involving the lymph nodes and lymphatic system, with 8,830 new cases diagnosed and accounting for 960 deaths each year in the United States (Siegel et al, 2021). In contrast with other cancers whose risk increases with age, the risk for HL increases in patients between 15 and 30 years of age, decreases during middle age, and is followed by another peak in adults older than 55 (NCCN, 2020). There are 2 main types of HL: classical HL, which accounts for 95% of cases in Western countries and is characterized by the presence of Reed-Sternberg cells, and nodular lymphocyte-predominant HL, which lacks these cells (NCCN, 2020). The last few decades have seen significant progress in the management of patients with HL, leading to improved outcomes. The 5-year relative survival rate is approximately 90% for early-stage disease (ACS, 2021). However, challenges remain, such as improving remission rates in patients with distant disease, who experience 5-year overall survival of approximately 81%, and improving quality of life of survivors, who may be at risk for secondary malignancies and late toxicities (ACS, 2021; Longley & Johnson, 2019).

Related Posts

Copyright © Oncology Data Advisor. All rights reserved.